Selection and expansion of natural killer cells for NK cell-based immunotherapy

Natural killer (NK) cells have been used in several clinical trials as adaptive immunotherapy. The low numbers of these cells in peripheral blood mononuclear cells (PBMC) have resulted in various approaches to preferentially expand primary NK cells from PBMC. While some clinical trials have used th...

Full description

Bibliographic Details
Main Authors:	Becker, Petra S. A., Suck, Garnet, Nowakowska, Paulina, Ullrich, Evelyn, Seifried, Erhard, Bader, Peter, Tonn, Torsten, Seidl, Christian
Format:	Online
Language:	English
Published:	Springer Berlin Heidelberg 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826432/

id	pubmed-4826432
recordtype	oai_dc
spelling	pubmed-48264322016-04-20 Selection and expansion of natural killer cells for NK cell-based immunotherapy Becker, Petra S. A. Suck, Garnet Nowakowska, Paulina Ullrich, Evelyn Seifried, Erhard Bader, Peter Tonn, Torsten Seidl, Christian Symposium-in-Writing Paper Natural killer (NK) cells have been used in several clinical trials as adaptive immunotherapy. The low numbers of these cells in peripheral blood mononuclear cells (PBMC) have resulted in various approaches to preferentially expand primary NK cells from PBMC. While some clinical trials have used the addition of interleukin 2 (IL-2) to co-stimulate the expansion of purified NK cells from allogeneic donors, recent studies have shown promising results in achieving in vitro expansion of NK cells to large numbers for adoptive immunotherapy. NK cell expansion requires multiple cell signals for survival, proliferation and activation. Thus, expansion strategies have been focused either to substitute these factors using autologous feeder cells or to use genetically modified allogeneic feeder cells. Recent developments in the clinical use of genetically modified NK cell lines with chimeric antigen receptors, the development of expansion protocols for the clinical use of NK cell from human embryonic stem cells and induced pluripotent stem cells are challenging improvements for NK cell-based immunotherapy. Transfer of several of these protocols to clinical-grade production of NK cells necessitates adaptation of good manufacturing practice conditions, and the development of freezing conditions to establish NK cell stocks will require some effort and, however, should enhance the therapeutic options of NK cells in clinical medicine. Springer Berlin Heidelberg 2016-01-25 2016 /pmc/articles/PMC4826432/ /pubmed/26810567 http://dx.doi.org/10.1007/s00262-016-1792-y Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Becker, Petra S. A. Suck, Garnet Nowakowska, Paulina Ullrich, Evelyn Seifried, Erhard Bader, Peter Tonn, Torsten Seidl, Christian
spellingShingle	Becker, Petra S. A. Suck, Garnet Nowakowska, Paulina Ullrich, Evelyn Seifried, Erhard Bader, Peter Tonn, Torsten Seidl, Christian Selection and expansion of natural killer cells for NK cell-based immunotherapy
author_facet	Becker, Petra S. A. Suck, Garnet Nowakowska, Paulina Ullrich, Evelyn Seifried, Erhard Bader, Peter Tonn, Torsten Seidl, Christian
author_sort	Becker, Petra S. A.
title	Selection and expansion of natural killer cells for NK cell-based immunotherapy
title_short	Selection and expansion of natural killer cells for NK cell-based immunotherapy
title_full	Selection and expansion of natural killer cells for NK cell-based immunotherapy
title_fullStr	Selection and expansion of natural killer cells for NK cell-based immunotherapy
title_full_unstemmed	Selection and expansion of natural killer cells for NK cell-based immunotherapy
title_sort	selection and expansion of natural killer cells for nk cell-based immunotherapy
description	Natural killer (NK) cells have been used in several clinical trials as adaptive immunotherapy. The low numbers of these cells in peripheral blood mononuclear cells (PBMC) have resulted in various approaches to preferentially expand primary NK cells from PBMC. While some clinical trials have used the addition of interleukin 2 (IL-2) to co-stimulate the expansion of purified NK cells from allogeneic donors, recent studies have shown promising results in achieving in vitro expansion of NK cells to large numbers for adoptive immunotherapy. NK cell expansion requires multiple cell signals for survival, proliferation and activation. Thus, expansion strategies have been focused either to substitute these factors using autologous feeder cells or to use genetically modified allogeneic feeder cells. Recent developments in the clinical use of genetically modified NK cell lines with chimeric antigen receptors, the development of expansion protocols for the clinical use of NK cell from human embryonic stem cells and induced pluripotent stem cells are challenging improvements for NK cell-based immunotherapy. Transfer of several of these protocols to clinical-grade production of NK cells necessitates adaptation of good manufacturing practice conditions, and the development of freezing conditions to establish NK cell stocks will require some effort and, however, should enhance the therapeutic options of NK cells in clinical medicine.
publisher	Springer Berlin Heidelberg
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826432/
_version_	1613564332670451712

Selection and expansion of natural killer cells for NK cell-based immunotherapy

Similar Items